A detailed history of Profund Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Profund Advisors LLC holds 42,841 shares of BMY stock, worth $2.47 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
42,841
Previous 41,794 2.51%
Holding current value
$2.47 Million
Previous $1.74 Million 27.78%
% of portfolio
0.09%
Previous 0.07%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $41,524 - $54,182
1,047 Added 2.51%
42,841 $2.22 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $26,082 - $34,337
-648 Reduced 1.53%
41,794 $1.74 Million
Q1 2024

May 08, 2024

SELL
$47.98 - $54.4 $131,992 - $149,654
-2,751 Reduced 6.09%
42,442 $2.3 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $147,379 - $175,864
3,040 Added 7.21%
45,193 $2.32 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $37,396 - $41,815
-646 Reduced 1.51%
42,153 $2.45 Million
Q2 2023

Aug 10, 2023

BUY
$63.71 - $70.74 $58,931 - $65,434
925 Added 2.21%
42,799 $2.74 Million
Q1 2023

May 11, 2023

SELL
$65.71 - $74.53 $44,157 - $50,084
-672 Reduced 1.58%
41,874 $2.9 Million
Q4 2022

Feb 02, 2023

SELL
$68.48 - $81.09 $45,950 - $54,411
-671 Reduced 1.55%
42,546 $3.06 Million
Q3 2022

Nov 04, 2022

SELL
$0.13 - $76.84 $346 - $205,009
-2,668 Reduced 5.81%
43,217 $3.07 Million
Q2 2022

Aug 01, 2022

SELL
$72.62 - $79.98 $445,160 - $490,277
-6,130 Reduced 11.79%
45,885 $3.53 Million
Q1 2022

May 10, 2022

SELL
$61.48 - $73.72 $482,495 - $578,554
-7,848 Reduced 13.11%
52,015 $3.8 Million
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $83,555 - $97,406
1,558 Added 2.67%
59,863 $3.73 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $24,259 - $28,417
410 Added 0.71%
58,305 $3.45 Million
Q2 2021

Aug 12, 2021

BUY
$61.91 - $67.42 $23,649 - $25,754
382 Added 0.66%
57,895 $3.87 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $359,244 - $404,043
-6,054 Reduced 9.52%
57,513 $3.63 Million
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $6,466 - $7,328
112 Added 0.18%
63,567 $3.94 Million
Q3 2020

Nov 13, 2020

SELL
$57.43 - $63.64 $716,439 - $793,909
-12,475 Reduced 16.43%
63,455 $3.83 Million
Q2 2020

Aug 03, 2020

BUY
$54.82 - $64.09 $818,462 - $956,863
14,930 Added 24.48%
75,930 $4.47 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $789,913 - $1.15 Million
-17,024 Reduced 21.82%
61,000 $3.4 Million
Q4 2019

Feb 18, 2020

BUY
$49.21 - $64.19 $1.16 Million - $1.51 Million
23,476 Added 43.04%
78,024 $5.01 Million
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $368,762 - $437,221
-8,622 Reduced 13.65%
54,548 $2.77 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $448,252 - $495,669
-10,046 Reduced 13.72%
63,170 $2.87 Million
Q1 2019

May 15, 2019

SELL
$45.12 - $53.8 $174,794 - $208,421
-3,874 Reduced 5.03%
73,216 $3.49 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $882,263 - $1.14 Million
-18,094 Reduced 19.01%
77,090 $4.01 Million
Q3 2018

Nov 13, 2018

BUY
$55.19 - $62.25 $1.24 Million - $1.4 Million
22,431 Added 30.83%
95,184 $5.91 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $308,536 - $384,555
-6,106 Reduced 7.74%
72,753 $4.03 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $256,397 - $295,165
-4,279 Reduced 5.15%
78,859 $4.99 Million
Q4 2017

Feb 14, 2018

SELL
$59.94 - $65.35 $1.33 Million - $1.45 Million
-22,232 Reduced 21.1%
83,138 $5.1 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $166,684 - $192,367
3,018 Added 2.95%
105,370 $6.72 Million
Q2 2017

Aug 11, 2017

BUY
N/A
102,352
102,352 $5.7 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.